Melatonin ameliorates the adrenal and pancreatic alterations in streptozotocin-induced diabetic rats: Clinical, biochemical, and descriptive histopathological studies

Atif Abdulwahab A. Oyouni1,2,*, Osama M. Al-Amer2,3, Fatma Aba Zakaib Ali4, Malik A. Altayar5, Mohammed M. Jalal5, Rayan Salem M. Albalawi4, Abdulwahab Ali Abuderman5, Khalaf F. Alsharif6, Waseem AlZamzami3, Ashraf Albrakati7 and Ehab Kotb Elmahallawy8*

Department of Biology, Faculty of Sciences, University of Tabuk, Tabuk, Saudi Arabia, 2Genome and Biotechnology Unit, Faculty of Sciences, University of Tabuk, Tabuk, Saudi Arabia, 3Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia, 4Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Sohag University, Sohag, Egypt, 5Department of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia, 6Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia, 7Department of Human Anatomy, College of Medicine, Taif University, Taif, Saudi Arabia, 8Department of Zoonotic Diseases, Faculty of Veterinary Medicine, Sohag University, Sohag, Egypt

Previous studies have demonstrated the beneficial effects of melatonin in diabetic rats. However, limited studies have been conducted on the potential effects of melatonin on the descriptive histopathological and morphometric findings in different compartments of the adrenal glands in diabetic animal models. In this study, using a streptozotocin (STZ)-induced diabetic rat model, we sought to examine histological alterations in the pancreas and adrenal glands and observe the effect of the administration of melatonin on the histopathology and morphology of the pancreas and the adrenal gland cortex and medulla that are altered by STZ-induced hyperglycemia. Rats were randomly assigned to four different groups: Group I, normal control; Group II, melatonin group (MT) (10 mg/kg/day); Group III, (diabetic STZ group), and Group IV, diabetic (STZ) + melatonin group (MT). Throughout the experiment, the animals’ fasting blood sugar levels were measured. Blood was obtained to determine the animals’ cumulative blood sugar levels after sacriﬁcation. For histological and morphometrical evaluations, the pancreatic and adrenal gland tissues were dissected and processed. Our results showed that diabetic rats receiving melatonin signiﬁcantly (P < 0.05) improved their fasting blood sugar and cumulative blood sugar levels compared to the diabetic group not receiving melatonin. Furthermore, histopathological examinations of the
Pancreatic and adrenal tissues of the diabetic rats indicated the occurrence of severe histopathological and morphometric changes. Morphometric analysis of the adrenals indicated a significant increase ($P < 0.05$) in the thickness of the cortex zones [zona glomerulosa (ZG), zona fasciculata (ZF), and zona reticularis (ZRI)] for the diabetic STZ group compared with other groups, and a significant decrease ($P < 0.05$) in the diameter of the inner adrenal gland medullas in the diabetic STZ rats compared to the other groups. Furthermore, treatment with melatonin restored these changes in both the pancreatic and adrenal gland tissues and produced a significant ($P < 0.05$) improvement in the cortex and medulla thickness compared to the untreated diabetic rats. Overall, melatonin significantly reduced the hyperglycemic levels of glucose in diabetic rats and reversed the majority of histopathological alterations in the tissues of the pancreas and adrenals, demonstrating its anti-diabetic activity.

**KEYWORDS**
diabetes mellitus, streptozotocin, melatonin, pancreas, adrenal gland

### Introduction

Diabetes mellitus (DM) is a frequently occurring life-threatening metabolic disorder that occurs worldwide. It is characterized by hyperglycemia that is caused by either insulin resistance or declined insulin secretion (1). The incidence of DM has been increasing markedly over the past several decades (2, 3). Previous investigations have demonstrated that DM can lead to various complications, including cardiovascular, neuropathy, retinopathy, nephropathy, and hepatic complications that are known to be the main causes of its associated mortality and morbidity (4, 5). Therefore, it is important that efficient methods for the management and prevention of DM and its complications be identified (6). It is known that induction of experimental diabetes can be caused by chemical destruction or surgical removal of part of the beta cells of the pancreas, by feeding with high-fat and high-sugar diets, and by drugs such as streptozotocin (STZ) and alloxan (7). The pancreatic beta-cell toxin streptozotocin (STZ) causes rapid and irreversible necrosis in these cells. The mechanism of STZ-induced cell injury includes increased reactive oxygen species generation, lipid peroxidation, protein oxidation, and DNA damage that results in cell death (8), producing an insulin deficiency similar to that in human diabetes type 1 (7).

It should be stressed that the occurrence of DM is closely associated with a dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis (9). A key stress-responsive organ, the adrenal gland is a component of both the HPA axis and the sympatho-adrenomedullary system (10). The adrenal glands are considered to be among the most important endocrine glands and are involved in many biological functions, including developmental, immune, inflammatory, osmoregulatory, and metabolic activities (11). The adrenal cortex produces several steroid hormones The three outer layers of the endocrine gland—the zona glomerulosa (ZG), the zona fasciculata (ZF), and the zona reticularis (ZRI)—as well as the inner medulla make up this structure. Numerous steroid hormones that are produced by the adrenal cortex have an impact on metabolism, stress response, and water and electrolyte equilibrium. Previous studies examining the relationship between diabetes and adrenal gland morphology found that patients with diabetes have larger adrenals (9). Polydipsia, polyphagia, and polyuria, which are DM symptoms, have been linked to the adrenal gland (12). All of the body’s major organs, including the heart, kidney, bones, muscles, and nervous system, are directly impacted by adrenal hormones, including the metabolic metabolism of carbohydrates, proteins, and lipids (11).

Melatonin (N-acetyl-5-methoxytryptamine), an endocrine substance produced from tryptophan, is synthesized primarily by the pineal gland and locally by numerous other tissue cells (13, 14). Investigations on the effects of pineal hormones on insulin secretion, carbohydrate metabolism, and blood glucose levels have been conducted (15, 16). Diabetes mellitus (DM) is associated with reduced serum concentrations of melatonin in diabetic Goto-Kakizaki rats, despite increased insulin levels in these animals (17). Furthermore, melatonin exhibits biological characteristics such as an anti-aging (18), antioxidant, anti-inflammatory (19), and antiparasitic properties (13, 20). Thus, among the stressors, oxidative stress might exist, and that influences the regulation of the HPA axis (21). Therefore, melatonin proves to be beneficial in those cases, as it is a well-known free radical scavenger, antioxidant and antiapoptotic agent (22). Melatonin exerts its functions at all levels, allowing cells to withstand the damage normally inflicted by radicals and radical-related creations (23). There is a broad literature regarding the assessment of adrenal hormones biochemically.
in patients with DM. However, the interactions between the adrenal cortex and medulla, as well as the structural alterations in adrenal cells’ histopathology, especially as they relate to STZ-induced DM, have not been well studied. Furthermore, little information is available on the histopathological changes that occur in the pancreas and adrenal glands in diabetic rats following melatonin administration. Therefore, there is an urgent need for the development of novel drug targets, including natural drugs, with no side effects. In the present study, our goal is to investigate the histopathological deviations that occur in the pancreas and adrenal glands in a streptozotocin (STZ)-induced DM rat model, which can shed light on the pathophysiology of the adrenal glands as the STZ-induced DM progresses. In addition, we planned to observe the effect of melatonin on the morphology of the adrenal cortex and medulla that are altered by STZ-induced hyperglycemia, which would provide basic knowledge regarding DM and its treatment.

Materials and methods

Ethical considerations

Animal handling and rights were conducted in accordance with the ethical committee guidelines of the Faculty of Veterinary Medicine, Sohag University. The ethical approval number is Sohag Vet/2021-1.

Materials

Drugs, chemicals, and oils

Streptozotocin powder, trisodium citrate dihydrate, and citric acid monohydrate were purchased from the Sigma-Aldrich Company (St. Louis, MO, USA). Melatonin (N-acetyl-5-methoxytryptamine) was purchased from FAGRON (Cat# 420 33457-24, Fagron, Nazareth, Belgium).

Animals

Forty mature male Wister albino rats, at 6 weeks of age with average body weights of 165–200 g, were purchased from the lab animal facility of the Faculty of Medicine, Sohag University, Sohag, Egypt. Animals were housed in clean and pathogen-free stainless-steel cages (five rats in each cage) with a 12 h light/12 h dark cycle, at 23 ± 2°C, and 50%–55% humidity. Rats were fed a standard pellet diet and water ad libitum throughout the experimental period. The bedding was changed continuously to ensure a clean environment. They were kept under these conditions for 1 week to acclimatize them before starting the experiment.

Experimental approach and design

To avoid using animals that were already infected with parasites, samples from the sediment and the supernatant after centrifugation were tested separately for the presence of parasitic eggs and/or larvae as part of the weekly fecal sample analysis. The rats were then divided into four groups of 10 each: Group I, a normal control group (n = 10) that was given regular rat food and water; Group II, the melatonin group (MT; n = 10) received an IP injection of melatonin, 10 mg/kg/day, for 4 weeks. The melatonin was dissolved in DMSO (1%, w/v) prior to injection (24–28). Group III, the diabetes STZ group (n = 10), were fasted the previous night for 12 h before inducing diabetes. Group IV, the diabetes (STZ) + melatonin group (MT; n = 10), were administrated melatonin IP (the same as for Group II) after treatment with STZ (the same as for the diabetic control positive Group III). For the induction of diabetes, a single IP injection of freshly prepared streptozotocin (45 mg/kg body weight, in 0.1 M cold citrate buffer, pH 4.5) was administered (25, 29). The animals were allowed free access to food, water, and a 15% solution of glucose overnight after the STZ injections to prevent hypoglycemic shock. The blood glucose levels were examined 3–6 days after the STZ injections (24, 30–32). Seventy-two hours after the injection of STZ, evidence of diabetes was observed by the occurrence of polyuria and polydipsia, and by measuring blood glucose levels from a blood sample taken from the tail vein, using a glucometer (On Call Plus, ACON Laboratories, Germany). Only those rats that received STZ and had blood glucose levels of 250 mg/dl or greater were considered diabetic and chosen for the study. All rats used for diabetic induction successfully developed diabetes following the STZ injection. Melatonin was administrated at the previously mentioned dose to the rats in the melatonin diabetic groups. Twelve hours after the final administration of melatonin, all the rats were sacrificed, and blood and tissue samples were taken.

Methods

Measurements of animal body weight

The body weights of the animals were measured before the start of the experiment and at the time of sacrifice.

Sample collection

Blood samples for the estimation of fasting blood sugar levels

Following blood collection from animal tail veins that had been disinfected with 10% alcohol during the experiment, fasting blood glucose levels were assessed. A tail prick was used to get a blood sample, which was then put on a test strip and put into a calibrated glucose meter (On Call Plus Glucometer, ACON...
of adrenal glands, the individual heights of the zona granulosa (ZG), zona fasciculata (ZF), and zona reticulata (ZR), and the height of the medulla (M) in H&E stained sections. A total of five samples from each group (five replicates) were included from each paraffin block; then five separate, non-overlapping sections were selected and inspected using low-power fields (×200) (40). Morphometry was performed in the Image Analysis Unit, Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Sohag University.

Statistical analysis

The data were expressed as the mean ± standard deviation (SD). The measurements obtained from the experimental groups were estimated statistically using GraphPad Prism, version 5 (San Diego, California, USA) using a one-way ANOVA with Tukey’s post hoc multiple comparison tests; P-values were used to compare and define the statistical significance between groups (41–43). A paired t-test was used to compare the body weight as well as fasting blood glucose levels between pre- and post-treatment. A difference was considered significant at P < 0.05.

Results

Clinical and biochemical profiles

As a consequence of STZ-induced diabetes, rats developed type 1 DM within 72 h and exhibited characteristic DM symptoms such as polyphagia, polydipsia, polyuria, and unexplained and significant (P ≤ 0.05) weight loss at the end of the experimental trial (Table 1). By comparing the STZ diabetic group to the STZ + MT-treated group and the control group, it was clear that the lowered body weights in the STZ diabetic group were significant (P ≤ 0.05) compared to the control negative and MT control groups (Table 1). Statistical analysis of fasting blood sugar during the first and fourth week of the experiment revealed that both groups, including the diabetic STZ group and the diabetic STZ + MT-treated group, had significantly (P ≤ 0.05) increased blood glucose levels compared to those in the control negative group. During the fourth week, the mean value for fasting blood sugar in the diabetic STZ + MT-treated group decreased significantly (P ≤ 0.05) compared to the control positive group; however, a difference was observed between the control negative and MT control groups (Table 2). When compared to the control negative and MT control groups, the diabetic STZ group’s cumulative blood sugar (HbA1c) levels were the highest and was significantly (P ≤ 0.05) higher, indicating that the rats in this group had diabetes. In the diabetic STZ + MT-treated group, the mean value of the level of cumulative blood sugar was significantly (P ≤ 0.05) higher when...
TABLE 1 Comparison of body weights in experimental groups in the STZ DM model.

| Groups                      | Body weight (g.) (Mean ± SD) | P-values of paired t-test |
|-----------------------------|------------------------------|--------------------------|
|                             | Initial body weight          | Final body weight         |
|                             | (before the experiment)      | (before sacrifice)        |
| Control                     | 177.1 ± 15.1                 | 207.6 ± 19.50             | 0.083 |
| MT control                  | 166.5 ± 5.02                 | 204.6 ± 10.11             | ***  |
| Diabetic (STZ)              | 192.4 ± 12.53                | 144.4 ± 13.48             | ***  |
| Diabetic STZ + MT-treated   | 190.3 ± 24.12                | 176.4 ± 24.46             | 0.351 |

Values are expressed as means ± SD.
Significant differences vs. the control group are marked by different asterisks through one-way ANOVA with Tukey’s post hoc test: *P ≤ 0.05, ***P ≤ 0.001, ns: Non significant.

The P-values of the paired t-test were 0.083, 0.352, 0.0006, and 0.351 for Control, MT control, Diabetic (STZ), and Diabetic STZ + MT-treated respectively. For each group (n = 10).

TABLE 2 Comparison of fasting blood glucose levels in the experimental groups.

| Groups                      | Fasted blood glucose level (Mean ± SD) | P-values of paired t-test |
|-----------------------------|----------------------------------------|--------------------------|
|                             | First week after diabetic induction    | Fourth week after diabetic induction |
|                             | (Before sacrifice)                     | (Before sacrifice)        |
| Control                     | 86.00 ± 5.888                          | 66.20 ± 7.190             | 0.123 |
| MT control                  | 105.0 ± 5.196                          | 66.25 ± 3.775             | ***  |
| Diabetic (STZ)              | 420.3 ± 52.67                          | 362.0 ± 123.1             | ***  |
| Diabetic STZ + MT-treated   | 395.3 ± 36.47                          | 196.7 ± 98.54             | (ns)  |

Values are expressed as means ± SD.
Significant differences vs. the control group are marked by different asterisks through one-way ANOVA with Tukey’s post hoc test: **P ≤ 0.01, ***P ≤ 0.001, ns: Non significant.

The P-values of the paired t-test were 0.123, 0.425, 0.0042, and 0.0002 for Control, MT control, Diabetic (STZ), and Diabetic STZ + MT-treated respectively. For each group (n = 10).

compared to the control and MT control groups, but it was also significantly lower compared to the diabetic STZ group (Table 3).

Histopathological assessments

Pancreatic tissue

The histopathological examinations of pancreatic tissue sections from the various experimental groups revealed the same normal histological structures in both the control negative and MT-treated rats and reflected the typical architecture of the pancreatic endocrine and exocrine parenchymal structures. Large pale oval regions with a distinct contour between the exocrine acini were visible as the endocrine islets of Langerhans. They were composed of numerous microscopic pale β cells and a few spherical, large, acidophilic cells encircling tiny blood capillaries (Figures 1A,C), in between numerous pyramidal acinar cells (Figures 1B,D). The tissue sections from the diabetic STZ rats without any treatment (control positive group) revealed a number of pathological findings, including distorted pancreatic lobules and a necrobiosis in cells of the islets of Langerhans in which the cytoplasm was homogenous and coagulated or vacuolated, the cytoplasm exhibited lysis, the nucleus was pyknotic, and other regions were lysed or absent, and the destroyed cells were replaced by fatty tissue (Figure 2A). This group’s exocrine parenchymal region exhibited atrophy, degeneration, and dissociation of a few exocrine acini (Figure 2A). Generally, the vascular system of the pancreatic tissue from this group (control positive group) revealed severe congestion with very thick walls (Figure 2B). Melatonin (MT) was concurrently administered to diabetic STZ rats in Group IV, which alleviated the pathological features that were noted in the diabetic STZ rats in Group III, where many normal pancreatic lobules with thin interlobular septa were found. The exocrine parenchyma had multiple pancreatic acini of normal size, and the islets of Langerhans and cells showed enhanced morphological
glomerulosa, the zona fasciculata, and the zona reticularis cell layers, except for some vacuolar degeneration. Animals in this group also contained normal adrenal medulla basophilic chromaffin cells with granular cytoplasm, while capillary medullary veins exhibited mild congestion (Figures 5A–D).

### Quantitative and semiquantitative histomorphometric studies

#### Scoring of pancreatic tissue injury

Compared to other groups, the diabetic STZ group's pancreatic histomorphometric results exhibited a significant difference ($P<0.05$) in the type of cell damage, which was manifested by atrophy of the islets of Langerhans (Figure 6A), vacuolar degeneration in the islets cells (Figure 6B), and vascular congestion (Figure 6C). Alternatively, diabetic rats treated with melatonin exhibited no significant change ($P<0.05$) compared with control groups.

#### Adrenal gland damage scoring

##### Size of adrenal gland

Histomorphometric measurements of the adrenal surface areas for the diabetic STZ group and the diabetic STZ + MT-treated group indicated that both were significantly increased ($P<0.05$) compared to the other groups. The adrenal size was significantly increased ($P<0.05$) in the diabetic STZ rats compared to the diabetic STZ + MT-treated group (Figure 7A).

##### Histomorphometry for thickness of cortex and medulla

There was a significant increase ($P<0.05$) in the thickness of the cortex zones (ZG, ZF, and ZR) for the diabetic STZ group compared to the other groups, and a significant decrease ($P<0.05$) in the diameter of the medulla in the adrenal gland of diabetic STZ rats compared to the control and other groups. The diabetic rats treated with melatonin exhibited a significant ($P<0.05$) improvement in the total thickness of the cortex and medulla compared to the untreated diabetic rats (Figures 7B–E).

### Discussion

Diabetes mellitus causes a variety of complications and affects many body organs, which are considered the principal triggers of its morbidity and mortality (4, 5).

The induction of experimental diabetes with streptozotocin caused rapid and irreversible pancreatic β-cell injury which involved the production of a massive generation of reactive oxygen species, lipid peroxidation, protein oxidation, and DNA damage resulting in the death of β-cells (8), all associated with insulin deficiency (7). As mentioned in previous studies,
FIGURE 1
Photomicrographs of pancreatic sections from the control negative group (A,B) and the MT control group (C,D) demonstrating normal pancreatic structure and architecture in the form of normal-sized islets of Langerhans and normal density of islet cells, normal exocrine acinar cells (thick arrows), a normal intralobular duct (arrowheads), and normal blood vessels (thin arrows). H&E stained. The bar size is indicated under each picture.

FIGURE 2
Photomicrographs of pancreatic sections from (A,B) of the diabetic STZ group showing (A) islets of Langerhans that experienced depletion and necrobiotic changes in its constituent cells, vacuolated degeneration in most of the cells (thin arrows), and capillary hemorrhage (black arrowheads). The exocrine acinar cells exhibit degeneration and dissociation (white arrowheads). (B) Severe dilatation and congestion blood vessels with thick vascular walls (arrows). (C,D) diabetic STZ + MT-treated group showing: (C) well-defined islets of Langerhans with proliferated cell populations (arrow) in between normal pyramidal acidophilic pancreatic acini (white arrowheads). (D) a normal vascular structure (thick arrow). H&E stained. The bar size is indicated under each picture.
DM instigated malfunction of the HPA axis and developed an alteration of the adrenal glands in Wistar rats (9).

Melatonin’s impact on the pancreatic tissues and adrenal glands in STZ-induced diabetes was examined in the current study. *N*-acetyl-5-methoxytryptamine, often known as melatonin, is a secretory byproduct of the pineal gland and other tissue cells that has potent scavenging activity for hydroxyl and peroxyl radicals, in addition to regulating the activity of antioxidant enzymes which is one of its functions (44, 45). Several previous studies have looked into the outcomes of administering melatonin in diabetic rats (15, 16). In the current work, rats developed glucosuria, hyperglycemia, and unexpected significant (*P* < 0.05) weight loss after diabetic induction compared to other groups (Table 1), as has been described in previous studies (46, 47). Melatonin in our study was unable to increase the body weight of the STZ-treated rats compared to control animals. However, the findings of body weight alterations were significant (*P* < 0.05) compared to the diabetic STZ-untreated rats. Parallel findings have been reported previously (45, 48). The sympathetic nervous system is thought to be implicated in this process by amplifying its effects on the brown and white adipose tissues, which cause them to mobilize and expend energy (16, 49).

In the research reported here, the administration of melatonin (10 mg/kg) in diabetic STZ rats induced a reduction in fasting blood glucose levels, which were equivalent to the healthy control levels (Table 2). Statistical analysis of fasting blood glucose levels after the first week of the experiment revealed that both diabetic STZ and STZ + MT-treated groups had significantly (*P* ≤ 0.05) elevated blood glucose levels compared to those of the control groups. After the fourth week, and before the animals were sacrificed, the blood glucose levels declined significantly (*P* ≤ 0.05) in the diabetic group treated with melatonin compared to the diabetic STZ-untreated group. Our results are in agreement with those of Doosti-Irani et al. (50) who documented that melatonin helps to maintain glycemic homeostasis by improving insulin sensitivity and lowering fasting blood sugar levels. As shown in Table 3, the uppermost level of HbA1c was monitored in the diabetic STZ group which was significantly (*P* ≤ 0.05) higher than the control groups. However, the diabetic STZ + MT-treated group expressed significantly (*P* ≤ 0.05) upraised HbA1c levels compared to the control and MT control groups, indicating that the treatment with melatonin had no discernible impact on the STZ-induced diabetic rats’ plasma glucose levels or the emergence of hyperglycemia. These findings are in agreement with the results of other researchers (49, 51). However, the HbA1c levels in diabetic STZ rats treated with melatonin were significantly lower compared to the diabetic STZ-untreated group. Our results agree with Sartori et al. (52) who also observed that melatonin therapy improved glucose tolerance. After 5 months of use, melatonin reduced HbA1c levels (53), and
enhanced glycemic control in diabetic patients (54). In addition, Shima et al. (55) had stated in their study that hyperglycemia instigated by the intracerebroventricular injection of 2-deoxy-D-glucose in rats was suppressed by melatonin. They reported that melatonin injections suppressed blood glucose levels, possibly through a brain site. A previous study (56) also stated that melatonin may decrease blood glucose levels through its role on catecholaminergic responses.

Some islets of Langerhans became severely atrophied in this study, and the surrounding exocrine tissue displayed degenerative changes. Some islets cells underwent necrotic changes, and the damaged cells occasionally were replaced by fatty tissue. The vascular system of the pancreas displayed considerable congestion, according to prior research (57, 58). These results may be due to DNA destruction caused by streptozotocin and ROS generation in small amounts with a decrease in antioxidant enzymes (59). A previous study (60) showed that in patients with poorly managed type II diabetes and metformin treatment, there was a greater cellular response after receiving 10 mg of melatonin. Another study (61) found that in obese people with acanthosis nigricans, treatment with 3 mg of melatonin per day, for 12 weeks, increased insulin sensitivity and decreased inflammation. Furthermore, the administration of melatonin diminished the levels of cytokines and immunoglobulins that consequently reduced pancreatic inflammation and allowed the regeneration of β cells (62). This was noticeable in the pancreatic tissue sections of the MT animals, where the size and structure of the islets recovered to some extent compared to the untreated diabetic group.

It should be stressed that the adrenal glands are involved in many biological functions including metabolic, osmoregulatory, immunological, inflammatory, and developmental processes (11). All the body’s major organs, including the heart, kidney, bones, muscles, and nervous system, are directly impacted by the changes that adrenal hormones cause in the metabolism of carbohydrates, proteins, and lipids (11). Additionally, the adrenal gland is critical in escalating DM symptoms (63). In this respect, several studies have illustrated that diabetes causes severe degeneration within the cells of the zona glomerulosa and the zona fasciculate of the adrenal cortex (9, 64). The
Photomicrographs of adrenal gland sections from the diabetic STZ + MT-treated group showing adrenal tissue regenerations that contain (A,B) normal thin connective tissue capsule (white arrowheads). (B) A remarkable improvement in cortical zonal partitions, a mild vacuolated ZG cell layer (ZG), mild vacuolation of the ZF cellular layer with normal arrangement (ZF), and a normal ZR cell layer (ZR). (A,C,D) Normal adrenal medulla basophilic chromaffin cells with granular cytoplasm (M). (D) Mild congestion in capillary medullary veins (V). H&E stained. The bar size is indicated under each picture.

Histomorphometry graph showing semiquantitative measurements of pancreatic tissue sections among the experimental groups. (A) Atrophy of the islets of Langerhans, (B) Vacuolar degeneration in the islets of Langerhans, and (C) Vascular congestion. Values are expressed as means ± SD. Significant differences vs. the control group are marked by different asterisks through one-way ANOVA with Tukey’s post hoc test: ns, non-significant; ***P ≤ 0.001.

HPA axis was found to be hyperactive in the presence of hyperglycemia, which raises plasma levels of both cortisol and corticosterone (65) and high blood glucose levels consequently happened. The histology of diabetic ZR is still unknown, though it has been shown that the adrenal cortex and medulla have medullary cellular interactions at various levels, with
cortical hormones promoting medullary hormonal synthesis and vice versa (66). Both adrenal hypertrophy and hyperplasia have been reported in STZ-induced diabetes (67). These reported findings in previous studies are in agreement with our present observations in relation to the histopathological effects of diabetes induced by STZ on cellular structures, the morphology of adrenal glands, thickening in the connective tissue capsule, distortion, hyperplasia, hypertrophy, vacuolation, and necrobiotic changes in the cortical structures of ZG, ZF, and ZR cells.

Furthermore, our present study revealed that adrenal medulla chromaffin cells were also atrophied and vacuolated and most of them lost their cytoplasmic granules. In addition, vascular congestion and dilatation were also observed. In the present study, the diabetic rats treated with melatonin exhibited a marked improvement in adrenal histological structures, and a remarkable restoration to most of its normal architecture in the ZG, ZF, and ZR cell layers, except for some vacuolar degeneration. In addition, the adrenal medulla contained normal basophilic chromaffin cells with granular cytoplasm and mild vascular congestion. When compared to diabetic rats that were left untreated, melatonin also dramatically decreased medulla overall thickness and was able to restore the morphology and hypertrophy of the cells in the adrenal cortex ($P < 0.05$). These results are consistent with previous research on the adrenal cortex (68).

Conclusions

The present study demonstrated that histopathological and morphological changes of the adrenal gland cortex compartments and medullary cellular structure occur in diabetic rats, and a restorative effect in these tissues happen following treatment with melatonin. In addition, the present study established the greatest effect of melatonin in restoring pancreatic cellular structures and adrenal cortex partitions ZG, ZF, and ZR, and for the first time demonstrated its effect in restoring adrenal medulla cellular structure and morphology.
in diabetic STZ rats. These findings will be useful in further pathological studies on controlling diabetic complications in other body organs.

Data availability statement

The original contributions presented in the study are included in the article-supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by the Research, Publication, and Ethics Committee of the Faculty of Veterinary Medicine, Sohag University, Egypt, which complies with all relevant Egyptian legislations in publication and research. The Institutional Review Board Number is Sohag Vet/2021-1.

Author contributions

AO, OA-A, FA, MA, MJ, RA, AAA, KA, WA, AA, and EE were involved in the conception of the idea, methodology design, performed data analysis and interpretation, and prepared the manuscript for publication and revision. All authors have read and approved the final manuscript.

References

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. (2014) 37(Supplement_1):S81–90. doi: 10.2337/dc14-5081

2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. (2010) 87:4-14. doi: 10.1016/j.diabres.2009.10.007

3. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. (2011) 94:311–21. doi: 10.1016/j.diabres.2011.10.029

4. Du W-h, Peng S-M, Liu Z-h, Shi L, Tan L-F, Zou X-Q. Hypoglycemic effect of the water extract of Pu-erh tea. J Agric Food Chem. (2012) 60:10126-32. doi: 10.1021/jf302426w

5. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. (2014) 103:137–49. doi: 10.1016/j.diabres.2013.11.002

6. Li T, Yang C, Huai Q, Guo F, Liu L, Feng R, et al. Effects of tea or tea extract on metabolic profiles in patients with type 2 diabetes mellitus: a meta-analysis of ten randomized controlled trials. Diabetes Metab Res Rev. (2016) 32:2–10. doi: 10.1002/dmrr.2641

7. El-Feky H, Salah A, Hussein Y, Sabry M. Histological study of the effect of induced diabetes on the zona glomerulosa of the adrenal cortex of adult male albino rat. Egypt J Histol. (2010) 33:17–22. doi: 10.1007/s00765-010-0090-3

8. Hidayat M, Mahar Y, Wasim B. Effect of melatonin on serum glucose and body weights in streptozotocin induced diabetes in albino rats. J Ayub Med Coll Abbottabad. (2015) 27:274-6.

9. Carsin-Vu A, Oubaya N, Mulé S, Janvier A, Delemer B, Soyer P, et al. MDCT linear and volumetric analysis of adrenal glands.

normative data and multiparametric assessment. Eur Radiol. (2016) 26:2494–501. doi: 10.1007/s00330-016-4063-y

10. Ulrich-Lai YM, Figueiredo HF, Ostrander MM, Choi DC, Engeland WC, Herman JP. Chronic stress induces adrenal hyperplasia and hypertrophy in a subregion-specific manner. Am J Physiol Endocrinol Metab. (2006) 291:E965-73. doi: 10.1152/ajpendo.00070.2006

11. Raees K, Ishfaq R, Ullah A, Tahir MZ, Abbas T, Tahir HM, et al. Histological and micrometric effects of diazinon exposure on adrenal medulla and cortex in mice. J Appl Anim Res. (2012) 40:267–72. doi: 10.1080/09712119.2012.672309

12. Fauci AS, Kasper DL, Hauser SL, Longo D, Jameson LJ. Harrison’s Manual of Medicine, 17th ed. New York, NY: McGraw-Hill (2009).

13. Elmahallawy EK, Ortega Luque J, Saleh Alowidi A, Gutierrez-Fernandez I, Sampedro-Martinez A, Rodriguez-Granger J, et al. Potential relevance of melatonin against some infectious agents: a review and assessment of recent research. Curr Med Chem. (2015) 22:3848–61. doi: 10.2174/0929867322666150827093730

14. Szewczyk PB, Dziuba AM, Poniewierka E. Melatonin-metabolism and the role of pineal hormone. Nurs Public Health. (2018) 8:135–9. doi: 10.17219/pph/77041

15. Agil A, Elmahallawy E, Rodriguez-Ferrer J, Adem A, Bastaki S, Al-Abbadi I, et al. Melatonin increases intracellular calcium in the liver, muscle, white adipose tissues and pancreas of diabetic obese rats. Food Funct. (2015) 6:2671–8. doi: 10.1039/C5FO00590F

16. Agil A, Navarro-Alarcon M, Ali FAZ, Albrakati A, Salagre D, Campoy C, et al. Melatonin enhances the mitochondrial functionality of brown adipose tissue in obese-diabetic rats. Antioxidants. (2021) 10:1482. doi: 10.3390/antiox10091482

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Funding

The authors would like to acknowledge the financial support for this work from the Deanship of Scientific Research (DSR), University of Tabuk, Saudi Arabia, under the no. 0131-1442-S.

Acknowledgments

The authors would like to express their gratitude and thanks to the government of Saudi Arabia, especially the University of Tabuk.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
58. Atta A, Saad S, Atta S, Mouneir S, Naar S, Desouky H, et al. Cucumis sativus and Cucurbita maxima extract attenuate diabetes-induced hepatic and pancreatic injury in a rat model. *J Physiol Pharmacol.* (2020) 71: 507–18. doi: 10.26402/jpp.2020.4.06

59. Eleazu CO, Eleazu KC, Chukwuma S, Essien UN. Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. *J Diabetes Metab Disord.* (2013) 12:1–7. doi: 10.1186/2251-6581-12-60

60. Kadhim HM, Ismail SH, Hussein KI, Bakir IH, Sahib AS, Khalaf BH, et al. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin. *J Pineal Res.* (2006) 41: 189–93. doi: 10.1111/j.1600-079X.2006.00353.x

61. Sun H, Wang X, Chen J, Gusdon AM, Song K, Li L, et al. Melatonin treatment improves insulin resistance and pigmentation in obese patients with *Acanthosis nigricans*. *Int J Endocrinol.* (2018) 2018: 1–7. doi: 10.1155/2018/2304746

62. Farid A, Moussa P, Youssef M, Hayatham M, Shamy A, Safwat G. Melatonin relieves diabetic complications and regenerates pancreatic beta cells by the reduction in NF-kB expression in streptozotocin induced diabetic rats melatonin: anti-diabetic drug. *Saudi J Biol Sci.* (2022) 29: 103313. doi: 10.1016/j.sjbs.2022.103313

63. Kasper L. *Harrisons Manual of Medicine*, 19th ed. New York, NY: McGraw-Hill Education (2016).

64. Schneller J, Reiser M, Beuschlein F, Oswald A, Pallauf A, Riester A, et al. Linear and volumetric evaluation of the adrenal gland—MDCT-based measurements of the adrenals. *Acad Radiol.* (2014) 21: 1465–74. doi: 10.1016/j.acra.2014.06.008

65. Rebuffat P, Belloni AS, Malendowicz LK, Mazzocchi G, Meneghelli V, Nuissdorfer GG. Effects of streptozotocin-induced experimental diabetes on the morphology and function of the zona fasciculata of rat adrenal cortex. *Virchows Archiv B.* (1988) 56: 13–9. doi: 10.1007/BF02889996

66. Haase M, Willenberg HS, Bornstein SR. Update on the corticomedullary interaction in the adrenal gland. *Pediatr Adrenal Dis.* (2011) 20: 28–37. doi: 10.1159/000321211

67. Elahi-Moghaddam Z, Behnam-Rassouli M, Mahdavi-Shahri N, Hajinejad-Bokhourne R, Khajooee E. Comparative study on the effects of type 1 and type 2 diabetes on structural changes and hormonal output of the adrenal cortex in male Wistar rats. *J Diabetes Metab Disord.* (2013) 12:1–6. doi: 10.1186/2251-6581-12-9

68. Mahar Y, Shoro AA, Hidayat M. Effect of melatonin on the morphology of adrenal cortex altered by streptozotocin. *PMJHS.* (2015) 9: 1213–6.